|
J Biol Chem, Vol. 273, Issue 36, 23335-23343, September 4, 1998
The Human Forkhead Protein FREAC-2 Contains Two Functionally
Redundant Activation Domains and Interacts with TBP and TFIIB*
Marika
Hellqvist,
Margit
Mahlapuu,
Åsa
Blixt,
Sven
Enerbäck, and
Peter
Carlsson
Department of Molecular Biology, Göteborg University,
Medicinaregatan 9C, Box 462, S-405 30 Göteborg, Sweden
 |
ABSTRACT |
Forkhead-related activator 2 (FREAC-2) is a human
transcription factor expressed in lung and placenta that binds to
cis-elements in several lung-specific genes. We have
identified the parts of FREAC-2 responsible for
trans-activation and found two functionally redundant
activation domains on the C-terminal side of the DNA binding forkhead
domain. Activation domain 1 consists of the most C-terminal 23 amino
acids of FREAC-2 and contains a sequence motif conserved in an
activation domain of another forkhead protein, FREAC-1. Activation
domain 2 is built up by three synergistic subdomains in the central
part of the FREAC-2 protein. FREAC-2 was shown to interact in
vitro with TBP and TFIIB. The target site for FREAC-2 on TBP was
localized to the N-terminal repeat in the core domain of TBP. TFIIB
binds FREAC-2 close to the cleft between its two globular domains. The
part of FREAC-2 that binds TBP was mapped to 21 amino acids in the
C-terminal end of the forkhead domain. This sequence is well conserved
among forkhead proteins, raising the possibility that interaction with
TBP may be a general characteristic of this family of transcription
factors. Overexpression of TFIIB potentiates activation by FREAC-2 in a manner dependent on the FREAC-2 activation domains. Nuclear
localization of FREAC-2 was found to depend on sequences from both ends
of the forkhead domain.
 |
INTRODUCTION |
Genes encoding transcription factors that contain a forkhead DNA
binding domain have been found in eucaryotic organisms from the
simplest unicellular fungi to mammals. It appears, however, to be in
the evolution of metazoans that this gene family expanded to the
complexity that we see in today's vertebrates. Whereas, for example,
the entire genome of Saccharomyces cerevisiae (1) contains 4 genes with a forkhead motif, over 50 mammalian forkhead genes have been
cloned so far (reviewed in Ref. 2). Consistent with this, forkhead
genes are involved in embryogenesis and pattern formation in
multicellular organisms. In fact, all known examples of inactivation of
forkhead genes result in more or less dramatic disturbances of
embryogenesis (3-14).
How is functional specificity maintained within a gene family with so
many closely related members? One level of specificity is DNA binding.
Distantly related members of the forkhead family may bind to completely
distinct DNA sequences (15-17). Even in cases in which the DNA binding
domains are more closely related and the binding specificities are
overlapping, there can as in the case of
FREAC-31 and FREAC-4 (18) be
differences in the relative affinities for a particular sequence that
may have profound biological significance (18-21). There are, however,
also several examples of forkhead proteins in which the DNA binding
domains are so similar that it is reasonable to assume that the
specificities are identical. The most extreme example is that of
FREAC-4 and FREAC-9, two human forkhead proteins that are encoded by
different genes and are coexpressed in certain cells. FREAC-4 and
FREAC-9 have DNA binding domains with 100% identity throughout their
105 amino acids, but they have no homologies outside the forkhead
domains (22). In such cases, the proteins will either be functionally
redundant, as appears to be the case with the two forkhead genes in the
sloppy paired locus of Drosophila (23), or
specificity will reside in other functions than DNA binding. An example
that illustrates that forkhead proteins expressed in the same tissue
and with indistinguishable DNA binding specificities can have distinct
biological functions is that of FREAC-1 and FREAC-2. Although both
proteins bind to and activate the surfactant protein B promoter, the
gene for another lung-specific protein, CC10, is only activated by
FREAC-1 due to the presence of a cell type-specific activation domain
in FREAC-1 (24).
The DNA binding function of forkhead proteins is well understood (25),
but far less is known about their activities as transcriptional regulators. The majority of forkhead proteins that have been
experimentally analyzed appear to be transcriptional activators, but
only in a few cases have the regions of the proteins responsible for
activation been identified. HNF3 activate transcription through four
regions (26), and Whn, encoded by the nude locus, contains
an acidic activation domain in the C terminus (27). The human forkhead protein FKHR has a potent activation domain that, when fused to the
heterologous DNA binding domain of PAX3 by a translocation, is
responsible for malignant transformation in alveolar rhabdomyosarcoma (28-30). Transcriptional trans-repression is known from
Genesis, a forkhead protein expressed in embryonic stem cells (16), and the proto-oncogene product c-Qin or BF1 (31, 32). In the latter case,
the repression domain is essential for the transforming ability of the
oncogenic version of the protein, v-Qin (33, 34).
Interaction with other cellular components is necessary for
transcription factors in conveying biological signals. Again, we know
very little about the interactions made by forkhead proteins, but a
role in the remodeling of chromatin structure as a step in
transcriptional activation has been proposed (35). The
Xenopus forkhead protein FAST-1 has been identified as a
direct target for transforming growth factor- /activin signaling and
shown to form a complex with the transforming growth factor- signal
transducer XMAD2 (36). The forkhead-associated domain is a sequence
motif found in some forkhead proteins, as well as in certain protein kinases, that has been proposed to participate in nuclear signaling (37).
The human forkhead gene FREAC-2 is, in the adult, expressed only in
lung and placenta (19), and the encoded protein is a transcriptional
activator (24). FREAC-2 binds the consensus sequence AACGTAAACAA (18,
19), and the amino acid sequence of the DNA binding domain is virtually
identical to that of another human forkhead protein, FREAC-1 (24). The
promoters of a number of genes that are specifically expressed in lung,
including the genes for surfactant apoproteins, contain binding sites
for FREAC-2 (24).
Herein, we describe mapping of functional domains in FREAC-2. We have
identified the regions responsible for transcriptional activation and
also shown that FREAC-2 interacts with components of the basal
transcriptional machinery. Finally, we have addressed the issue of
subcellular localization and identified the parts of FREAC-2 that
targets the protein to the nucleus.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs and Mutagenesis--
The FREAC-2 expression
plasmid has been described elsewhere (24). Constructs expressing
truncated FREAC-2 proteins were generated by creating deletions in the
FREAC-2 plasmid with restriction enzymes or Bal31 exonuclease.
Triple alanine substitution mutations in the FREAC-2 coding
sequence were generated with oligonucleotide directed in
vitro mutagenesis, essentially as described previously (38), using the following mutagenic primers: GCCATCGAATGCCACGCGGCCGCCACGAGCCCTGCGGC (m295-297), AAGCAGCCGCCTGCCGCGGCCGCCAGCAGCAACCCCGC (m319-321), TCCAGCATGTCCTCCGCGGCCGCGGAGCAGAGCTACTT (m338-340),
GTGGGACTGCCCCGTGCGGCCGCTCACTCTACTCCAGT (m360-362), and
AATGGGATTTCTTCTGCGGCCGCCTCAGCTAGCGGGTC (m383-385). The m173 mutant was
created by insertion of a double-stranded oligonucleotide adapter
(GCGGCCGCACGC and TGCGGCCGCGCG) into the unique DraIII site
of FREAC-2. Internal, in frame deletions in FREAC-2 were created by
joining fragments from the triple alanine substitution constructs at
the NotI sites introduced by mutagenesis.
A vector for expression of Gal4 fusions (pNG4) was created by insertion
of a polylinker (CCGGAATTGTCGACTGCGGCCGCAAGCTTTCTAGATAGCTAGCTAG) downstream of codon 147 of Gal4 in pCMV-Gal4 (38). Constructs expressing amino-terminally truncated FREAC-2 proteins fused to the
Gal4 DNA binding domain were then made by cloning
NotI-XbaI fragments from the triple alanine
substitution constructs between the corresponding sites in pNG4.
Fragments encoding internal regions of the FREAC-2
trans-activation domain were generated by polymerase chain
reaction with primers tagged with SalI (forward) and
XbaI (reverse) sites. These polymerase chain reaction
products were inserted between the SalI and XbaI
sites of pNG4 and verified by sequencing.
The reporter 4×FREAC-luc (24) contains four FREAC-2 binding sites
upstream of a minimal apoB promoter that drives the expression of
luciferase. To create a reporter construct for Gal4 fusion proteins
(Gal4-luc), six copies of a double-stranded oligonucleotide containing
a Gal4 binding site (GATCCGGACTGTCCTCCGAGATC) was cloned into the
BglII site of apoB-luc (24).
FREAC-2 expression constructs were modified for in vitro
transcription-translation by deleting the SacI fragment
containing the CMV promoter in the pEVRF0 vector (39), thereby moving
the T7 promoter of the vector immediately upstream of the FREAC-2 cDNA sequence.
To express TFIIB in mammalian cells, the human TFIIB cDNA (40) was
cloned between the BamHI and XbaI sites of pEV3S
(39).
Transfections, Luciferase Assays, and Gel Shift Assays--
Cell
lines COS-7 and HepG2 were grown on collagen-coated plastic in
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf
serum, penicillin and streptomycin. Liposome-mediated transfections
were performed as described previously (24) in 24-well tissue culture
plates using Lipofectin or LipofectAMINE (Life Technologies, Inc.). Two
days posttransfection, the medium was removed, and the cells were
rinsed once with 0.5× Tris-buffered saline (1× Tris-buffered saline
is 50 mM Tris-Cl, pH 7.8, 130 mM NaCl, 10 mM KCl, 5 mM MgCl2). Cell lysis
buffer (25 mM Tris-phosphate, pH 7.8, 2 mM
dithiothreitol, 2 mM
1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100) was added (50 µl/well), and the plates were incubated on ice for 15 min. When extracts for gel
shift assays should be made from the nuclei after the luciferase assay,
protease inhibitors (20 µg/ml each of leupeptin, chymostatin and
aprotinin; 5 µg/ml each of pepstatin A and antipain; 1 mM phenylmethylsulfonyl fluoride) were included in the cell lysis buffer.
The plates were tilted, and the cytoplasmic extract was carefully
removed, without disturbing the nuclei attached to the bottom of the
well, and assayed for luciferase activity. The plates were put back on
ice, and 30 µl of nuclear extraction buffer (100 mM
Hepes, pH 7.9, 500 mM KCl, 25 mM
MgCl2, 35% glycerol, 10 mM dithiothreitol,
protease inhibitors) was added to each well. The contents of the wells
were transferred to 1.5-ml tubes and cleared by centrifugation.
Supernatants were diluted 5-fold with H2O and assayed for
FREAC-2 or Gal4 DNA binding activities in gel shifts (24) with the
probes GATCCAACGTAAACAATCCGAGATC (FREAC-2) and GATCCGGACTGTCCTCCGAGATC
(Gal4). Each construct was transfected in duplicate in at least three
independent transfections.
Bacterial Protein Expression--
Amino acids 146-408 of
FREAC-2 was expressed as a histidine-tagged protein in
Escherichia coli M15[pREP4] using the vector pQE30
(Qiagen). Induced bacteria were lysed in 6 M guanidine-HCl, 0.1 M sodium phosphate, 10 mM Tris-Cl, 1 mM -mercaptoethanol, pH 8.0, and mixed with nickel-NTA
(Qiagen) resin. The resin was packed in a column and washed with 8 M urea, 0.1 M sodium phosphate, 10 mM Tris-Cl, 1 mM -mercaptoethanol, pH 8.0 (Buffer B), and the bound protein was renatured with a linear gradient
from Buffer B to 100 mM NaCl, 20 mM Tris-Cl, pH
7.4, 20% glycerol, 2 mM -mercaptoethanol, 0.02%
NaN3 using an Amersham Pharmacia Biotech FPLC.
Epitope (HA)-tagged human TBP (41) was expressed in E. coli
BL21(DE3)[pLysS], and the soluble protein was immobilized on protein
A-Sepharose beads (Amersham Pharmacia Biotech) that had first been
saturated with the anti-HA monoclonal antibody 12CA5 (42).
Protein-Protein Interaction Assays--
Coupled in
vitro transcription-translation of general transcription factors
and parts of FREAC-2 was performed with TNT-T7 (Promega) and
[35S]methionine (Amersham Pharmacia Biotech). In
vitro-translated general transcription factors were mixed with
FREAC-2/nickel-NTA beads, and in vitro-translated FREAC-2
peptides were mixed with TBP-Sepharose beads in 50 µl of 20 mM Tris-Cl, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 10% glycerol, 0.1% Nonidet P-40, 2 mM -mercaptoethanol, 0.1 mg/ml bovine serum albumin.
When nickel-NTA beads were used, 10 mM imidazole was
included in the binding and washing buffers to eliminate nonspecific
binding. To verify that retention of the labeled protein was due to
true protein-protein interactions, rather than being mediated by
protein-DNA interactions, 35 units of DNase I was included in the
binding reaction. Control binding reactions were performed with
nickel-NTA beads or protein A-Sepharose beads saturated with 12CA5
monoclonal antibody. The binding reactions were rocked gently for
1 h at 4 °C, and the beads were collected by low speed
centrifugation and washed four times with binding buffer. Bound
proteins were detected by SDS-polyacrylamide gel electrophoresis and
fluorography.
Green Fluorescent Protein (GFP) Fusions--
The FREAC-2
cDNA and parts thereof generated by polymerase chain reaction were
cloned between the BamHI and XbaI sites in the
GFP fusion vector pGFP-C1 (CLONTECH). Transfection
of these constructs into COS-7 cells generated fusion proteins in which parts of FREAC-2 are fused to the C terminus of GFP. Cells were seeded
on a coverslip in a tissue culture dish and transfected with liposomes
as described above. Twenty-four hours posttransfection, the cells were
rinsed in phosphate-buffered saline and mounted in a drop of
phosphate-buffered saline on a microscope slide. The subcellular
localization of the fusion proteins was visualized in vivo
by fluorescence microscopy and photographed through a fluorescein
isothiocyanate filter set
 |
RESULTS |
Mapping of trans-Activation Domains in FREAC-2--
To define
which parts of the FREAC-2 protein are responsible for
trans-activation of transcription, we generated a series of
5' and 3' deletions in the FREAC-2 cDNA (Fig.
1A). Expression constructs for
these truncated FREAC-2 proteins were transfected into mammalian cell
lines together with a luciferase reporter plasmid containing FREAC-2
binding sites upstream of a minimal promoter. Several cell lines
derived from different tissues, including the lung cell lines NIH-H441
and WI38, were tested, and the activation properties of the FREAC-2
derivatives were found to be similar in all of the cell lines. We
therefore chose to use the human hepatoma cell line HepG2 and the
monkey kidney cell line COS-7, because high and reproducible
transfection efficiencies were obtained with these cells.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 1.
A, transcriptional activation by FREAC-2
and deletion mutants. HepG2 cells were cotransfected with expression
constructs encoding the different FREAC-2 variants and a luciferase
reporter containing four FREAC-2 binding sites. Numbers
refer to the amino acids present in each protein. Vector
denotes the result of cotransfection with an empty expression plasmid.
wt (wild type) is the full-length FREAC-2 protein (amino
acids 1-408). The luciferase activity produced by the reporter when
cotransfected with the empty vector is defined as 1. Error
bars represent the S.E. B, effect of substitutions and
internal deletions in FREAC-2 on transcriptional activation.
Numbers refer to amino acids in FREAC-2 that have been
replaced with alanines (constructs with names starting with "m") or
deleted (constructs with names starting with " "). Luciferase
activity is expressed as a percentage of that produced by wild type
FREAC-2. C, gel shift assay with a probe containing a
FREAC-2 binding site and nuclear extracts from cells transfected with
the constructs used in panel A. D, gel shift
assay with a probe containing a FREAC-2 binding site and nuclear
extracts from cells transfected with the constructs used in panel
B.
|
|
Deletion of the amino acids on the N-terminal side of the forkhead
domain did not influence activation by FREAC-2, whereas deletions from
the C-terminal end reduced its activation of the reporter (Fig.
1A). To establish whether the drop in activity reflects
removal of activation domains or simply instability of the truncated
proteins, we made extracts from the nuclei of transfected cells and
used gel shift to assay for proteins with FREAC-2 DNA binding
specificity. As shown in Fig. 1C, two of the truncated proteins (1-387 and 1-293) were partially degraded, and the
luciferase activities produced in the corresponding transfections (Fig.
1A) are therefore unreliable. However, the rest of the
proteins appear to be stable and to bind DNA normally. FREAC-2 proteins
truncated at amino acid 241 or 189 inhibit luciferase expression from
the reporter to less than 5% of the value obtained with cotransfection of the empty cloning vector. The mechanism behind this inhibition is
not known, but the simplest explanation is that endogenous forkhead
proteins with overlapping DNA binding specificities are capable of
activating the reporter and are displaced by FREAC-2. Consistent with
this explanation, the 4×FREAC-luc reporter produces an activity
severalfold higher than the corresponding construct without FREAC-2
sites, apoB-luc, and the truncated FREAC-2 proteins fail to inhibit the
luciferase expression from apoB-luc (data not shown).
The 1-328 truncated protein activates with approximately one-half the
potency of the full-length protein, and further deletions, moving the C
terminus of the protein from 328 to 241, resulted in a 100-fold drop in
activity. We took this to indicate the importance of amino acid
sequences between 241 and 328 for transcriptional activation, with a
possible contribution from regions C-terminal of 328. To analyze this
part of the protein further, we used in vitro mutagenesis to
introduce six triple alanine substitutions in the part of the FREAC-2
protein C-terminal of the forkhead DNA binding domain. The restriction
enzyme sites introduced by mutagenesis were also used to create
internal deletions in the FREAC-2 cDNA (Fig. 1B).
Surprisingly, deletions in the region between 241 and 328 did not lead
to significant reductions of activity. In fact, deletion of everything
C-terminal of the forkhead domain, except for the last 23 amino acids
( 173-385), did not impair transcriptional activation by FREAC-2 in
this assay (Fig. 1B). This result suggested that the most
C-terminal 23 amino acids of FREAC-2 can act as an independent
activation domain. To test whether this is the case or the context of
the DNA binding forkhead domain is a prerequisite for activation, we
fused segments of different length from the C-terminal half of FREAC-2
with the DNA binding domain of Gal4. When the ability of these fusion
proteins to activate a reporter containing multiple Gal4 binding sites were analyzed, the most C-terminal 23 amino acids of FREAC-2 were again
found to act as a potent and independent activation domain (Fig.
2A). This part of the FREAC-2
protein will be referred to as activation domain 1 (AD1).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 2.
Activation of a Gal4-luciferase reporter by
parts of FREAC-2 fused to the DNA binding domain of Gal4.
A. The last 23 amino acids of FREAC-2 act as a potent
trans-activation domain (AD1) when fused to the DNA binding
domain of Gal4. Numbers refer to amino acids of FREAC-2 fused to the
DNA binding domain of Gal4. The luciferase activity produced by the
reporter when cotransfected with a plasmid expressing just the Gal4 DNA
binding domain is defined as 1. Error bars represent the
S.E. B, the internal activation domain (AD2) of FREAC-2 is
built up by several subdomains that contribute to activation in a
synergistic fashion. C, gel shift assay with a probe
containing a Gal4 binding site and nuclear extracts from cells
transfected with the constructs used in panels A and
B. Because Gal4 binds DNA as a dimer and fusion proteins are
sensitive to proteolytic cleavage in the C-terminal end of the Gal4 DNA
binding domain, there may be up to three shifted bands in each lane.
The band with the lowest mobility represents a DNA-bound dimer of the
full-length fusion protein; the band with intermediate mobility results
from heterodimerization between a full-length fusion protein and a
truncated Gal4 DNA binding domain; and finally, the fastest migrating
complex, which consists of dimers of Gal4 DNA binding domains, has the
same mobility in all lanes and is visible only for the most labile
fusion proteins. The empty Gal4 construct also produces three bands
(only the top two are visible in this figure) because the amino acids
encoded by the polylinker in the pNG4 vector add a tail to the Gal4
protein.
|
|
The results of transfections with deletion mutants and Gal4 fusions
suggested that FREAC-2 contains at least two independent and
functionally redundant activation domains. More specifically, the
100-fold difference between 1-241 and 1-328 (Fig. 1A)
indicated the presence of activating sequences in the central part of
the protein (from now on referred to as activation domain 2 (AD2)), whereas the activities of 173-385 and G4(386-408) (Figs.
1B and 2A) define AD1 in the C terminus. As the
results of the internal deletions showed (Fig. 1B), it was
impossible to investigate AD2 with AD1 present; even deletion of more
than half the FREAC-2 protein ( 173-385) did not reduce activity as
long as AD1 was left intact (Fig. 1B). Analysis of AD2 was
further complicated by the fact that a precise deletion of AD1 from
FREAC-2 (1-387) yielded an unstable protein (Fig. 1C). To
identify the activating regions that constitute AD2, we therefore fused
sequences from the internal part of FREAC-2 to the DNA binding domain
of Gal4. The 212 amino acids from the C-terminal end of the forkhead
domain to the N-terminal end of AD1 (amino acids 174-388) were divided into four subregions of 51-56 amino acids each (Fig. 2B).
When analyzed by cotransfection with the Gal4-luciferase reporter, the
first (174-225), second (225-278), and fourth (332-388) subregions contributed to activation (Fig. 2B). Individually, none of
the subregions produced any substantial activation, but together
(G4(174-388)), they acted in a synergistic manner and activated the
Gal4 reporter 150-fold (Fig. 2B). Judged from gel shifts
with extracts from transfected cells, all the FREAC-2/Gal4 fusion
proteins, except G4(174-408), appear to be stable and to bind DNA
normally (Fig. 2C). In the case of G4(174-408) the major
part of the Gal4 DNA binding activity consists of dimers of just the
Gal4 DNA binding domain, which arise from proteolysis, and very little
of the full-length dimer is seen. Because the truncated Gal4 dimers
bind DNA and compete with the full-length protein for the binding sites
but do not activate transcription, this may account for the lower activity of G4(174-408) compared with G4(174-388).
FREAC-2 Interacts with General Transcription Factors--
The
parts of FREAC-2 responsible for activation of transcription thus
appear to be located in the region C-terminal of the forkhead domain.
To investigate whether this part of the protein interacts through
direct protein-protein binding with components of the transcriptional
preinitiation complex, we used a pull-down assay. Amino acids 146-408
of FREAC-2 were expressed in bacteria as a His-tagged protein and
immobilized on a nickel-agarose affinity matrix. Human general
transcription factors, synthesized and 35S-labeled by
in vitro translation, were assayed for specific binding to
the FREAC-2 coated beads (Fig. 3). TFIIA
(the 55-kDa precursor of the - and -subunits), TFIIB, TBP,
TFIIE , TFIIE , TAFII32, and TAFII55 were
tested. Two proteins, TBP and TFIIB, were found to interact
specifically with FREAC-2, whereas none bound to the control beads
consisting of nickel-agarose (Fig. 3).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 3.
FREAC-2 interacts with TBP and TFIIB.
Human general transcription factors were synthesized,
35S-labeled by in vitro translation, and tested
for binding to immobilized FREAC-2 in a pull-down assay. Loaded in the
input lane is 5% of the protein used in the binding
reaction. FREAC-2 beads are His-tagged amino acids 146-408
of FREAC-2 immobilized on nickel-agarose, and control beads
are nickel-agarose without protein.
|
|
The domains of the general transcription factors responsible for the
interaction with FREAC-2 were mapped by repeating the FREAC-2 binding
assay with truncated forms of TBP and TFIIB (Fig. 4). The conserved TBP core domain in the
C-terminal half of the protein contains two imperfect (38% identity)
61 amino acid repeats (41) and is folded in a pseudosymmetrical saddle
shape (43-46). Proteins from which part (TBP1-267) or all (TBP1-236)
of the C-terminal repeat had been deleted bound FREAC-2 with
undiminished affinity, but when the deletion was extended to remove
part of the N-terminal repeat (TBP1-180), the interaction was lost.
Thus, the second half of the first repeat of core TBP (amino acids
181-236) appears to be the target for FREAC-2 binding. Although not
similar in either amino acid sequence or three-dimensional structure,
the organization of the TFIIB protein resembles that of TBP in having a
unique N-terminal part followed by a C-terminal core domain made up of
two imperfect (20% identity) 84-amino acid repeats (40). The two
repeats in the core of TFIIB folds into two separate domains with
similar three-dimensional structure (47). Deletion of more than half of
the last of the two repeats in TFIIB (TFIIB1-265 and TFIIB1-251) did
not impede binding to FREAC-2, whereas deletion into the first repeat
did (TFIIB1-173). As with TBP, the part of TFIIB that interacts with
FREAC-2 is within the core of the protein, or more precisely, between
amino acids 174 and 251; i.e. in the C-terminal end of the
N-terminal repeat or the N-terminal end of the C-terminal repeat.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
FREAC-2 interacts with the core domains of
TBP and TFIIB. Pull-down assay performed as described in Fig. 3,
but with deletion mutants of TBP and TFIIB. The lanes labeled
input each show 5% of the protein used for the binding
reactions, and those labeled FREAC-2 beads show the protein
retained on the FREAC-2 affinity matrix. Numbers refer to
the amino acids present in the truncated TBP and TFIIB proteins, and
wt (wild type) designates the full-length proteins.
|
|
Given the localization of activation domains in the FREAC-2 protein, we
wanted to determine whether the amino acid sequences interacting with
the general transcription factors coincided with any of the regions
responsible for activation. To do this, we expressed epitope-tagged
human TBP in bacteria and bound to protein A-Sepharose with a
monoclonal antibody. Various parts of FREAC-2 were synthesized by
in vitro translation and tested for binding to the
immobilized TBP protein (Fig. 5). None of
the regions that were identified as activators of transcription
interacted with TBP. Instead, the TBP binding region of FREAC-2 was
localized to amino acids 146-166, i.e. to the most
C-terminal end of the forkhead domain. Because this stretch of amino
acids is part of the DNA binding domain of FREAC-2 although unable to
bind DNA by itself we repeated the binding assay in the presence of a
high concentration of DNase I to ensure that the retention of FREAC-2 resulted from a bona fide protein-protein interaction and
was not mediated by DNA-protein interactions. Incubation with nuclease did not influence the binding between FREAC-2 and TBP, which confirms that DNA does not mediate this association (Fig. 5).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 5.
The part of FREAC-2 that interacts with TBP
is the most C-terminal 21 amino acids of the forkhead domain
(146-166). Parts of FREAC-2 were synthesized and 35S
labeled by in vitro translation and tested for binding to
immobilized TBP. Loaded in the input lane is 5% of the
protein used in the binding reaction. The lane labeled TBP
beads shows epitope-tagged human TBP expressed in E. coli and immobilized on protein A-Sepharose with a monoclonal
antibody, and the lane labeled control beads shows protein
A-Sepharose with just the monoclonal antibody. +DNase I
indicates that DNase I was included in the binding reaction to
eliminate possible contributions from protein-DNA interactions to the
retention of the labeled protein.
|
|
In cotransfection experiments, overexpression of TFIIB potentiates the
activation by FREAC-2 approximately 10-fold (Fig.
6). This TFIIB effect depends on the
integrity of the activation domains and was lost when FREAC-2 was
truncated at amino acid 189 (Fig. 6).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
FREAC-2 dependent activation of transcription
by TFIIB. COS-7 cells were transfected with the 4×FREAC-luc
reporter and the indicated FREAC-2 constructs. Shaded
bars represent the ratio between luciferase activities
produced by cotransfections with and without a TFIIB expression
plasmid. The averages of four transfection experiments are shown, and
error bars represent the S.E.
|
|
The Forkhead Domain of FREAC-2 Contains a Bipartite Nuclear
Localization Signal--
As a DNA-binding protein and transcription
factor, FREAC-2 must enter the nucleus to perform its activity. In
order to identify amino acid sequences in FREAC-2 that may function as
a nuclear localization signal (NLS), we fused the FREAC-2 cDNA, and
fragments thereof, with the coding sequence of GFP (Fig.
7B) and analyzed the
subcellular localization of GFP fusion proteins in transfected COS-7
cells. While GFP alone was distributed throughout the cell, FREAC-2
fused to GFP was found exclusively in the nucleus (Fig. 7B);
a result that confirms that FREAC-2 is indeed a nuclear protein. The
minimal part of FREAC-2 that is entirely localized to the nucleus
comprises amino acids 64-166, i.e. exactly the forkhead domain. When deletions were made in the forkhead domain from either the
C or N terminus, the resulting fusion proteins were still preferentially nuclear, but with a significant amount of the proteins present in the cytoplasm. Sixteen amino acids from the C terminus of
the forkhead domain (amino acids 151-166) gave a predominantly nuclear
localization to the fusion protein, but a similar result was obtained
when the forkhead domain with these same 16 amino acids deleted was
fused to GFP (amino acids 58-152). In contrast, 38 amino acids
(115-152) from the central part of the forkhead domain did not
contribute to nuclear localization; the distribution of this fusion
protein was indistinguishable from that of GFP alone. The forkhead
domain thus appears to contain sequences in its N terminus, as well as
its C terminus, that aid in translocation of the protein from the
cytoplasm to the nucleus. Both regions are necessary for a complete
nuclear localization.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 7.
The forkhead domain of FREAC-2 contains a
bipartite nuclear localization signal. A, fluorescence
micrographs of COS-7 cells transfected with plasmids expressing GFP and
fusions between GFP and parts of FREAC-2. Numbers refer to
amino acids of FREAC-2 fused to GFP. Green fluorescence
reveals the localization of the GFP moiety, and areas of intense
fluorescence appear white or yellowish due to
overexposure of the film. B, schematic representation of the
parts of FREAC-2 that were fused to GFP. The hatched box
corresponds to the forkhead domain.
|
|
 |
DISCUSSION |
FREAC-2 activates transcription through two independent activation
domains, AD1 and AD2. AD1 is well defined as the most C-terminal 23 amino acids of the protein. Also, when fused to the heterologous DNA
binding domain of Gal4, these 23 amino acids activate expression from a
reporter construct, which confirms their function as a bona
fide activation domain. The amino acid sequence of AD1 is homologous to the C terminus of FREAC-1 (Fig. 7B) (24). This is the only region, apart from the forkhead domains, where FREAC-1 and
FREAC-2 have any higher degree of similarity. As might be expected, the
C terminus of FREAC-1 has activating properties similar to AD1 of
FREAC-2.2 A transcriptional
activation domain from the extreme C terminus of another forkhead
protein, HNF3 , has been described (49). However, there is no
similarity in amino acid sequence between the activation domains of
HNF3 and AD1 in FREAC-2.
AD2 is spread out over approximately 200 amino acids and thus spans
half of the FREAC-2 protein. In contrast to AD1, it consists of
noncontiguous ranges of amino acids. Activation by AD2 may depend on
the tertiary structure of the protein to bring amino acid motifs from
distant locations together into a functional structure. The reasons for
treating it as a single activation domain are the following
observations: when the 215 amino acids containing the AD2 activity were
divided into four subregions, none of these subregions was able to
activate on its own. But when combined, three subregions (numbers 1, 2, and 4) enhanced each other's activation in a synergistic rather than
additive manner. If the mechanism by which AD2 activates transcription involves binding of a target protein, these results are compatible with
interaction with a single target and contribution to the binding by all
the three activating subregions. The amino acid sequence of AD2 shows
no obvious homology to other known proteins; it is rich in serines,
glycines, histidines, and prolines; it contains a stretch of
poly-histidine; and it has comparatively few charged amino acids.
No synergy appears to arise from the presence of both AD1 and AD2 in
FREAC-2. When analyzed by deletions in the FREAC-2 protein as well
as by fusion to Gal4, no significant changes in reporter gene activity
were observed as a result of removal of either AD1 or AD2, as long as
the other was left intact. With the assay and reporter used, the two
activation domains thus appear to be functionally redundant, which of
course does not exclude the possibility that they may serve distinct
purposes in other contexts.
Several lines of evidence support the idea that transcriptional
activation involves recruitment of the transcriptional preinitiation machinery to the promoter DNA, and activation domains of transcription factors have been shown to interact specifically with components of the
general transcription complex (reviewed in Ref. 50). We were therefore
interested to see whether the FREAC-2 activation domains interacted
with any of the general transcription factors involved in PolII
transcription. A panel of general transcription factors were tested for
interaction with the C-terminal part of FREAC-2, containing the
activation domains AD1 and AD2, in a protein-protein binding assay. Two
factors, TBP and TFIIB, were found to bind specifically to FREAC-2.
These two components of the general transcription complex have been
found to interact with the activation domains of several other
transcription factors, e.g. NF B, C/EBP , and VP16
(51-54).
Transcriptional activation by FREAC-2 is potentiated by overexpression
of TFIIB, and this effect depends on the C-terminal part of FREAC-2
containing the activation domains. One component in the transcription
regulating activity of FREAC-2 thus appears to be activation through
recruitment of TFIIB by the C-terminal part of the protein.
However, when we mapped the TBP interaction on the FREAC-2 protein
(Fig. 8), the amino acids responsible for
binding to TBP were found to be nonoverlapping with the activation
domains. Instead, TBP was found to interact with 21 amino acids in the
C terminus of the forkhead domain. The function of this interaction
remains obscure, but it does not appear to be required for activation by AD1 or AD2 because both retain their activities when fused to the
heterologous DNA binding domain of Gal4. The region of FREAC-2 that
binds TBP is well conserved within the forkhead family (19), and it is
therefore possible that the ability to interact with TBP is a general
characteristic of forkhead proteins.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
A, schematic figure summarizing the
functional domains of FREAC-2. B, homology between the
C-terminal end of FREAC-2, containing the activation domain AD1, and
the C-terminal end of FREAC-1 (24).
|
|
The target sites for FREAC-2 on both TBP and TFIIB are located in the
conserved core domains of the proteins. The core of TBP embraces the
TATA box DNA like a saddle, where the sequence repeats correspond to
the two sides of the saddle (43-46). The two repeats of the TFIIB core
are folded into two separate globular domains of similar structure,
connected by a short linker sequence (47). The cleft between the two
domains of this dumbbell-shaped protein binds to the stirrup of the
C-terminal half of the TBP saddle, and the two TFIIB domains are
arranged more or less along the axis of the DNA (47). Because FREAC-2
contacts the N-terminal repeat of the TBP core, it will bind to the
half of the saddle that faces away from TFIIB. On TFIIB, the site of
FREAC-2 interaction is close to the cleft where the TBP stirrup binds
and could be on either the C-terminal or the N-terminal domain.
Consequently, the target sites for FREAC-2 on TBP and TFIIB are not
juxtaposed when these proteins are bound to the TATA box, and if the
interactions are to take place simultaneously, the parts of FREAC-2
involved in binding have to be well separated.
NLSs are amino acid motifs that will cause a protein to be translocated
to the nucleus through docking with NLS receptors (55). Usually, an NLS
is a short stretch rich in basic amino acids with a bias toward lysines
over arginines (56, 57). However, many deviations from this general
rule have been described, and a classification with different types of
NLS motifs has been suggested (58). In DNA-binding proteins, the NLS is
almost invariably found within, or in immediate proximity to, the DNA
binding domain (59). From an evolutionary point of view, this
arrangement makes sense. Nuclear localization is a prerequisite for DNA
binding, and making the NLS an intrinsic property of the DNA binding
domain will ensure that this function is always at hand when the DNA binding motif is used in new contexts, e.g. through exon
shuffling. Hence, it is not surprising that the NLS of FREAC-2 is found
within the forkhead domain. From inspection of the primary structure, the stretch of basic amino acids in the C-terminal end of the forkhead
domain appears to be the best candidate, and when these 16 amino acids,
GSFRRRPRGFRRKCQA (151-166), were fused to GFP, the localization of the
fusion protein was indeed preferentially nuclear. However, a
significant amount of the protein was still cytoplasmic, in contrast to
what we saw with the entire forkhead domain, in which all of the GFP
fusion protein was nuclear. Furthermore, when the basic stretch of 16 amino acids was removed from the forkhead domain, the resulting GFP
fusion protein was still preferentially nuclear, although a
considerable cytoplasmic leakage confirmed the importance of the basic
stretch for complete nuclear localization. The fact that 38 amino acids
from the middle of the forkhead domain have no NLS activity shows that
the NLS is bipartite and requires sequences from both ends of the
forkhead domain. Because both the N-terminal and the C-terminal
sequences have substantial NLS activity when isolated, they are perhaps
better described as two independent NLSs, neither of which is
sufficient for complete nuclear localization. Given the high degree of
sequence conservation within the forkhead domain, it is not unlikely
that the NLS is organized in a similar manner throughout this protein
family, although examples from the steroid receptor family show that
the location of the NLS can differ considerably among proteins with the
same general structure of their DNA binding domains (48). That a
requirement for sequences from both ends of the forkhead domain for
nuclear localization is not unique for FREAC-2 is shown by studies of
HNF3 , in which an intact forkhead domain has been reported to be
necessary for nuclear localization (26).
 |
ACKNOWLEDGEMENTS |
We thank Drs. R. D. Roeder, Z. F. Burton, D. Reinberg, and R. Tjian for clones of general transcription
factors. Thanks are also due to Kerstin Dahlenborg and Lennart Asp for
technical assistance.
 |
FOOTNOTES |
*
This work was supported by grants from The Swedish Cancer
Foundation, the Fredrik and Ingrid Thuring Foundation, and the Magnus Bergvall Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 46-31-7733804;
Fax: 46-31-7733801; E-mail: peter.carlsson{at}molbio.gu.se.
The abbreviations used are:
FREAC, forkhead-related activator; GFP, green fluorescent protein; AD, activation domain; NLS, nuclear localization signal.
2
Mahlapuu, M., Pelto-Huikko, M., Aitola, M.,
Enerbäck, S., and Carlsson, P. (1998) Dev. Biol., in
press.
 |
REFERENCES |
-
Goffeau, A. et al. (1997) Nature 387, (suppl.) 1-105
-
Kaufmann, E.,
and Knochel, W.
(1996)
Mech. Dev.
57,
3-20[CrossRef][Medline]
[Order article via Infotrieve]
-
Ang, S. L.,
and Rossant, J.
(1994)
Cell
78,
561-574[CrossRef][Medline]
[Order article via Infotrieve]
-
Weinstein, D. C.,
Ruiz i Altaba, A.,
Chen, W. S.,
Hoodless, P.,
Prezioso, V. R.,
Jessell, T. M.,
and Darnell, J., Jr.
(1994)
Cell
78,
575-588[CrossRef][Medline]
[Order article via Infotrieve]
-
Xuan, S.,
Baptista, C. A.,
Balas, G.,
Tao, W.,
Soares, V. C.,
and Lai, E.
(1995)
Neuron
14,
1141-1152[CrossRef][Medline]
[Order article via Infotrieve]
-
Hatini, V.,
Huh, S. O.,
Herzlinger, D.,
Soares, V. C.,
and Lai, E.
(1996)
Genes Dev.
10,
1467-1478[Abstract/Free Full Text]
-
Nehls, M.,
Pfeifer, D.,
Schorpp, M.,
Hedrich, H.,
and Boehm, T.
(1994)
Nature
372,
103-107[CrossRef][Medline]
[Order article via Infotrieve]
-
Weigel, D.,
Jurgens, G.,
Kuttner, F.,
Seifert, E.,
and Jäckle, H.
(1989)
Cell
57,
645-658[CrossRef][Medline]
[Order article via Infotrieve]
-
Häcker, U.,
Kaufmann, E.,
Hartmann, C.,
Jürgens, G.,
Knöchel, W.,
and Jäckle, H.
(1995)
EMBO J.
14,
5306-5317[Medline]
[Order article via Infotrieve]
-
Grossniklaus, U.,
Pearson, R. K.,
and Gehring, W. J.
(1992)
Genes Dev.
6,
1030-1051[Abstract/Free Full Text]
-
Miller, L. M.,
Gallegos, M. E.,
Morisseau, B. A.,
and Kim, S. K.
(1993)
Genes Dev.
7,
933-947[Abstract/Free Full Text]
-
Winnier, G. E.,
Hargett, L.,
and Hogan, B. L.
(1997)
Genes Dev.
11,
926-940[Abstract/Free Full Text]
-
Labosky, P. A.,
Winnier, G. E.,
Jetton, T. L.,
Hargett, L.,
Ryan, A. K.,
Rosenfeld, M. G.,
Parlow, A. F.,
and Hogan, B. L.
(1997)
Development
124,
1263-1274[Abstract]
-
Dou, C.,
Ye, X.,
Stewart, C.,
Lai, E.,
and Li, S. C.
(1997)
Neuron
18,
539-551[CrossRef][Medline]
[Order article via Infotrieve]
-
Li, C.,
Lai, C. F.,
Sigman, D. S.,
and Gaynor, R. B.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
7739-7743[Abstract/Free Full Text]
-
Sutton, J.,
Costa, R.,
Klug, M.,
Field, L.,
Xu, D.,
Largaespada, D. A.,
Fletcher, C. F.,
Jenkins, N. A.,
Copeland, N. G.,
Klemsz, M.,
and Hromas, R.
(1996)
J. Biol. Chem.
271,
23126-23133[Abstract/Free Full Text]
-
Schlake, T.,
Schorpp, M.,
Nehls, M.,
and Boehm, T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3842-3847[Abstract/Free Full Text]
-
Pierrou, S.,
Enerbäck, S.,
and Carlsson, P.
(1995)
Anal. Biochem.
229,
99-105[CrossRef][Medline]
[Order article via Infotrieve]
-
Pierrou, S.,
Hellqvist, M.,
Samuelsson, L.,
Enerbäck, S.,
and Carlsson, P.
(1994)
EMBO J.
13,
5002-5012[Medline]
[Order article via Infotrieve]
-
Overdier, D. G.,
Porcella, A.,
and Costa, R. H.
(1994)
Mol. Cell. Biol.
14,
2755-2766[Abstract/Free Full Text]
-
Kaufmann, E.,
Muller, D.,
and Knochel, W.
(1995)
J. Mol. Biol.
248,
239-254[Medline]
[Order article via Infotrieve]
-
Ernstsson, S.,
Betz, R.,
Lagercrantz, S.,
Larsson, C.,
Erickson, S.,
Cederberg, A.,
Carlsson, P.,
and Enerbäck, S.
(1997)
Genomics
46,
78-85[CrossRef][Medline]
[Order article via Infotrieve]
-
Cadigan, K. M.,
Grossniklaus, U.,
and Gehring, W. J.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
6324-6328[Abstract/Free Full Text]
-
Hellqvist, M.,
Mahlapuu, M.,
Samuelsson, L.,
Enerbäck, S.,
and Carlsson, P.
(1996)
J. Biol. Chem.
271,
4482-4490[Abstract/Free Full Text]
-
Clark, K. L.,
Halay, E. D.,
Lai, E.,
and Burley, S. K.
(1993)
Nature
364,
412-420[CrossRef][Medline]
[Order article via Infotrieve]
-
Qian, X.,
and Costa, R. H.
(1995)
Nucleic Acids Res.
23,
1184-1191[Abstract/Free Full Text]
-
Schuddekopf, K.,
Schorpp, M.,
and Boehm, T.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9661-9664[Abstract/Free Full Text]
-
Scheidler, S.,
Fredericks, W. J.,
Rauscher, F. r.,
Barr, F. G.,
and Vogt, P. K.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9805-9809[Abstract/Free Full Text]
-
Bennicelli, J. L.,
Edwards, R. H.,
and Barr, F. G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5455-5459[Abstract/Free Full Text]
-
Sublett, J. E.,
Jeon, I. S.,
and Shapiro, D. N.
(1995)
Oncogene
11,
545-552[Medline]
[Order article via Infotrieve]
-
Tao, W.,
and Lai, E.
(1992)
Neuron
8,
957-966[CrossRef][Medline]
[Order article via Infotrieve]
-
Li, J.,
and Vogt, P. K.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
4490-4494[Abstract/Free Full Text]
-
Li, J.,
Chang, H. W.,
Lai, E.,
Parker, E. J.,
and Vogt, P. K.
(1995)
Cancer Res.
55,
5540-5544[Abstract/Free Full Text]
-
Chang, H. W.,
Li, J.,
and Vogt, P. K.
(1996)
Oncogene
13,
441-444[Medline]
[Order article via Infotrieve]
-
McPherson, C. E.,
Shim, E. Y.,
Friedman, D. S.,
and Zaret, K. S.
(1993)
Cell
75,
387-398[CrossRef][Medline]
[Order article via Infotrieve]
-
Chen, X.,
Rubock, M. J.,
and Whitman, M.
(1996)
Nature
383,
691-696[CrossRef][Medline]
[Order article via Infotrieve]
-
Hofmann, K.,
and Bucher, P.
(1995)
Trends Biochem. Sci.
20,
347-349[CrossRef][Medline]
[Order article via Infotrieve]
-
Carlsson, P.,
Waterman, M. L.,
and Jones, K. A.
(1993)
Genes Dev.
7,
2418-2430[Abstract/Free Full Text]
-
Matthias, P.,
Muller, M. M.,
Schreiber, E.,
Rusconi, S.,
and Schaffner, W.
(1989)
Nucleic Acids Res.
17,
6418[Free Full Text]
-
Malik, S.,
Hisatake, K.,
Sumimoto, H.,
Horikoshi, M.,
and Roeder, R. G.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
9553-9557[Abstract/Free Full Text]
-
Hoffman, A.,
Sinn, E.,
Yamamoto, T.,
Wang, J.,
Roy, A.,
Horikoshi, M.,
and Roeder, R. G.
(1990)
Nature
346,
387-390[CrossRef][Medline]
[Order article via Infotrieve]
-
Wilson, I. A.,
Niman, H. L.,
Houghten, R. A.,
Cherenson, A. R.,
Connolly, M. L.,
and Lerner, R. A.
(1984)
Cell
37,
767-778[CrossRef][Medline]
[Order article via Infotrieve]
-
Kim, J. L.,
Nikolov, D. B.,
and Burley, S. K.
(1993)
Nature
365,
520-527[CrossRef][Medline]
[Order article via Infotrieve]
-
Kim, Y.,
Geiger, J. H.,
Hahn, S.,
and Sigler, P. B.
(1993)
Nature
365,
512-520[CrossRef][Medline]
[Order article via Infotrieve]
-
Chasman, D. I.,
Flaherty, K. M.,
Sharp, P. A.,
and Kornberg, R. D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8174-8178[Abstract/Free Full Text]
-
Nikolov, D. B.,
Hu, S. H.,
Lin, J.,
Gasch, A.,
Hoffmann, A.,
Horikoshi, M.,
Chua, N. H.,
Roeder, R. G.,
and Burley, S. K.
(1992)
Nature
360,
40-46[CrossRef][Medline]
[Order article via Infotrieve]
-
Nikolov, D. B.,
Chen, H.,
Halay, E. D.,
Usheva, A. A.,
Hisatake, K.,
Lee, D. K.,
Roeder, R. G.,
and Burley, S. K.
(1995)
Nature
377,
119-128[CrossRef][Medline]
[Order article via Infotrieve]
-
Ylikomi, T.,
Bocquel, M. T.,
Berry, M.,
Gronemeyer, H.,
and Chambon, P.
(1992)
EMBO J.
11,
3681-3694[Medline]
[Order article via Infotrieve]
-
Pani, L.,
Overdier, D. G.,
Porcella, A.,
Qian, X.,
Lai, E.,
and Costa, R. H.
(1992)
Mol. Cell. Biol.
12,
3723-3732[Abstract/Free Full Text]
-
Ptashne, M.,
and Gann, A.
(1997)
Nature
386,
569-577[CrossRef][Medline]
[Order article via Infotrieve]
-
Nerlov, C.,
and Ziff, E. B.
(1995)
EMBO J.
14,
4318-4328[Medline]
[Order article via Infotrieve]
-
Paal, K.,
Baeuerle, P. A.,
and Schmitz, M. L.
(1997)
Nucleic Acids Res.
25,
1050-1055[Abstract/Free Full Text]
-
Stringer, K. F.,
Ingles, C. J.,
and Greenblatt, J.
(1990)
Nature
345,
783-786[CrossRef][Medline]
[Order article via Infotrieve]
-
Lin, Y. S.,
Ha, I.,
Maldonado, E.,
Reinberg, D.,
and Green, M. R.
(1991)
Nature
353,
569-571[CrossRef][Medline]
[Order article via Infotrieve]
-
Gorlich, D.,
Prehn, S.,
Laskey, R. A.,
and Hartmann, E.
(1994)
Cell
79,
767-778[CrossRef][Medline]
[Order article via Infotrieve]
-
Osborne, M. A.,
and Silver, P. A.
(1993)
Annu. Rev. Biochem.
62,
219-254[CrossRef][Medline]
[Order article via Infotrieve]
-
Dingwall, C.,
and Laskey, R. A.
(1991)
Trends Biochem. Sci.
16,
478-481[CrossRef][Medline]
[Order article via Infotrieve]
-
Boulikas, T.
(1993)
Crit. Rev. Eukaryotic Gene Expression
3,
193-227[Medline]
[Order article via Infotrieve]
-
LaCasse, E. C.,
and Lefebvre, Y. A.
(1995)
Nucleic Acids Res.
23,
1647-1656[Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

|